AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01334736 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: After participants have completed the data collection portion of the SHIELD visit, the research assistant will provide the participant with an informational flyer regarding the risks of tobacco smoking and benefits of tobacco cessation. The participant will be provided the phone number for the Tobacco Quit Line in Maryland as well as a list of local tobacco cessation programs. Any questions will be answered by the research assistant. If the participant inquires about nicotine replacement therapy, they will be advised to contact their primary care provider to discuss potential therapeutic options. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
Study NCT01334736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lung age
Description: For individuals randomized to spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be verbally informed of spirometric results. It will be explained that lung function normally reduces with age and that smoking can damage lung as if they were aging more rapidly than normal using visual depictions. Their lung function estimates based on their chronological age and lung age will be provided. They will be informed that smoking cessation would slow the aging of their lungs. After questions are answered, the participant will receive a written report that includes enumeration of their lung age and chronological age. At initial and follow-up visits, the research assistant will provide the participant with the same informational flyer and Tobacco Quit Line in Maryland as the usual care intervention.
Study NCT01334736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: For individuals randomized to CM, after completion of data collection, it will be explained to the participant that they will receive monetary compensation for biological confirmation of tobacco cessation. At each visit, exhaled carbon monoxide levels will be checked. If the subject has a negative CO level, they will be compensated. If a participant has a CO consistent with recent tobacco use, (s)he will receive the payment for attending the visit, but no additional payment at that visit. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
Study NCT01334736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lung age + Contingency Management
Description: For individuals randomized to the combined contingency management + spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be described the process of contingency management as outlined above. Following this, the research assistant will then describe lung age to the participant as described above. At the end of this process, the participant will then receive the informational flyer, quit line and local tobacco cessation program information similar to the usual care intervention. At each follow-up visit, after obtaining CO level and questionnaire outcomes, appropriate CM payment, review of participant's baseline lung age and informational flyer will occur.
Study NCT03333460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
Study NCT03333460 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
Study NCT02369627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid HIV Self-Test (OraQuick® In-home HIV Test)
Description: The participant will utilize materials and directions contained within the OraQuick In-Home HIV Test kit to properly perform a rapid HIV self-test. The participant will first swab his upper and lower gums using an Oral Swab Test Stick. The participant will then place this device in a test tube, and the results will be displayed in the Test Window within 20 minutes. Test results expire after 40 minutes.
Study NCT02369627 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Home-Based HIV Test (Home Access Express)
Description: The participant will utilize materials and directions contained within the Home Access Express HIV-1 Test System to properly perform a conventional home-based HIV test. The participant is required to gather a blood sample by lancing his finger. Blood samples are collected by placing drops of blood on a packaged specimen card. The participant will then mail his blood sample to the Home Access laboratory using a self-addressed, pre-paid shipping envelope. The Home Access laboratory will process the blood sample, and the participant is required to call the facility to learn his HIV test result.
Study NCT02369627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community/Medical-Based HIV Test
Description: The participant will receive a link to a CDC website (https://gettested.cdc.gov) to search for HIV testing locations in his surroudning community. This resource website will provide the participant with places that offer HIV testing for free or at a low cost. The participant also has the option of going to places that can use his insurance or charge for testing. The pariticant is responsible to pay for any testing costs.
Study NCT00002594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given IV
Study NCT04792541 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Study NCT00002594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00002594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT03373877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Dosing will be in accordance with current package insert and dose subject was on during study entry.
Study NCT03485560 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ACE CSD
Description: Topical application of the ACE CSD 4 times daily.
Study NCT02590497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging
Description: Undergo diffusion weighted MRI
Study NCT02590497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Undergo gadolinium-enhanced MRI
Study NCT02590497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Tissue genetic analysis
Study NCT02590497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo gadolinium-enhanced MRI
Study NCT02590497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo 3D volumetric T1-weighted sequence
Study NCT02590497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo FLAIR sequence
Study NCT02590497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion Magnetic Resonance Imaging
Description: Undergo perfusion MRI
Study NCT03004638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI6012 40 mg
Description: Participants received 3 doses of 40 milligram (mg) MEDI6012 IV on Days 1, 8, and 15.
Study NCT02065895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIGH error
Description: Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 1.33 times the true glucose value (analogous to higher gain lower target).
Study NCT00002594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Study NCT00002594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Study NCT00002594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT05288673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1210
Description: ALXN1210 was administered by IV infusion over 5 periods, 1 dose per period: Period 1, induction; Periods 2-5, maintenance. Participants received a total of 5 doses of 400 or 800 mg, each administered every 28 days.
Study NCT02360709 — intervention group
Intervention type: DEVICE
Intervention: CRE8 sirolimus-eluting stent
Description: The CRE8 stent system consists of a sirolimus eluting coronary stent firmly held on the distal end of a semicompliant balloon catheter. This stent is made of cobalt chromium alloy and is coated with a thin carbon film.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
Study NCT05288673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered by IV infusion over 5 periods, 1 dose per period. Participants received the same volume and infusion rate as specified for each ALXN1210 dose (400 or 800 mg).
Study NCT01016821 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone
Description: Intravenous, 1 mg, 5 times, in every 5 minutes, duration of drug administration 25 minutes
Study NCT04413669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: white light bronchoscopy & autofluorescence bronchoscopy
Description: White light bronchoscopy and autofluorescence bronchoscopy were carried out，and Take a biopsy for abnormal bronchial mucosa
Study NCT03113825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Imaging device
Description: Fluorescence imaging of the of the primary tumor specimen, any secondary breast specimens, and lymph nodes will be performed.
Study NCT03113825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-620
Description: AVB-620 will be administered IV before the surgical procedure.
Study NCT03843255 — intervention group
Intervention type: OTHER
Intervention: Part 1: DCM Cohort
Description: Patients with a confirmed diagnosis of DCM will have samples that undergo whole genome sequencing and biomarker analysis
Study NCT03843255 — intervention group
Intervention type: OTHER
Intervention: Part 2: Heritable CV Diseases and Family Members
Description: Biomarker analysis will be undertaken on samples
Study NCT00176852 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan, Fludarabine, ATG, TLI
Description: Busulfan 0.8 mg/kg/dose intravenous (IV) Days -8 and -7 Fludarabine 35 mg/m2 IV Days -6 through -2 Antithymocyte globulin (ATG) 30 mg/kg IV Days -2 and -1 Total lymphoid radiation 300 cGy
Study NCT00176852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan, Cyclophosphamide, ATG, GCSF
Description: Busulfan 0.8 mg/kg/dose intravenous (IV) Days -9 through -6 Cyclophosphamide 50 mg/kg IV Days -5 through -2 ATG 30 mg/kg IV Day -1 GCSF 5 mcg/kg/day IV until ANC >2500 x 2 days.
Study NCT00176852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath, Fludarabine, Cyclophosphamide
Description: Receives Campath-1H 0.2 mg/kg Days -10 through -6, Fludarabine 35 mg/m2 intravenous (IV) Days -6 through -2, total body irradiation (TBI) 300 cGy Day -1.
Study NCT00176852 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 300 cGY Day -1
Study NCT00176852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: Given Day 0
Study NCT01220089 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard maintenance
Description: Participants will receive written materials in months 7-18
Study NCT01220089 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensified maintenance
Description: Participants will continue with in-person counseling visits in months 7-18
Study NCT01373476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qideng Mingmu capsule
Description: High dosage group (4 Qideng Mingmu capsules each time): 4#, po, tid,24 weeks; Middle dosage group (2 Qideng Mingmu capsules plus 2 placebos each time):4#, po, tid,24 weeks;Low dosage group (1 Qideng Mingmu capsule plus 2 placebos each time):3#, po, tid,24 weeks.
Study NCT01373476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo group (4 placebos each time):4#, po, tid,24 weeks.
Study NCT01501201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric By-Pass
Description: Bariatric surgery laparoscopic Roux-en-Y Gastric Bypass (RYGBP)
Study NCT01501201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: optimized medical management
Description: group receiving an optimized medical management, among patients with obesity and poorly controlled type 2 diabetes
Study NCT00411801 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Uniplas
Description: Uniplas will be provided frozen in sterile plastic bags.
Study NCT00411801 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cryosupernatant plasma
Description: Cryosupernatant plasma will be provided frozen in sterile plastic bags.
Study NCT01202994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Flutemetamol
Description: All subjects will undergo a PET scan with 18F-PIB, within six months of also undergoing an FDG-PET scan (PET scans will occur on separate days).~For the 18F-PIB PET scan: Approximately 185 MBq (5 mCi) of 18F-PIB will be injected intravenously and PET data collected for each subject.~The FDG-PET scan will follow the same procedures as routine scans obtained in a clinical setting (approximately 370 MBq of 18F-FDG will be injected intravenously and PET data collected for each subject). FDG-PET data will be used to correlate metabolic changes and for anatomic co-registration of 18F-PIB images.
Study NCT02964052 — intervention group
Intervention type: OTHER
Intervention: Brain CT imaging
Description: Investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. Investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.
Study NCT04009473 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SEGOVA procedure
Description: SEGOVA procedure includes - Stem cell therapy, G - Growth factor Platelet Plasma Rich therapy and in Vitro Activation of the ovaries.
Study NCT00681577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: URLC10, KOC1, VEGFR1 and VEGFR2
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
Study NCT05799859 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of coronally advanced flap (CAF) and collagen matrix (CM)
Study NCT05799859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of coronally advanced flap (CAF) and collagen matrix (CM) and additional application of enamel matrix derivatives (EMD).
Study NCT04499235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Topical mometasone furoate
Study NCT04499235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate
Description: Topical mometasone furoate
Study NCT04499235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKST4290
Description: Oral AKST4290
Study NCT04499235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo
Study NCT00736931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Brivaracetam 10 mg tablets
Study NCT00736931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam
Description: 500mg tablets
Study NCT00736931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lorazepam
Description: lorazepam 2 mg over encapsulated tablets
Study NCT00736931 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules
Study NCT02071758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEISH-F3 + SLA-SE
Study NCT02071758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEISH-F3 + GLA-SE
Study NCT01989195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT
Description: EACH SUBJECT UNDERWENT 2 CARDIAC MRI PROCEDURES: ONE WITH MAGNEVIST (GADOLINIUM), ONE WITH SEEMORE (MANGANESE) REAGENT~* CARDIAC MRI USING STANDARD DOSE OF 0.2mMOL/KG MAGNEVIST IV (IN THE VEIN)~* CARDIAC MRI USING SEEMORE REAGENT, DOSE: 0.35CC/KG IV (IN THE VEIN) 1 WEEK AFTER GADOLINIUM MRI
Study NCT03497988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon
Description: The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.
Study NCT03497988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
Study NCT02065895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NO error
Description: Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL and glucose-value-used-for-control equal to the true glucose value.
Study NCT02065895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LOW error
Description: Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 0.8 times the true glucose value (analogous to lower gain higher target).
Study NCT04611048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thermal QST (CDT, WDT, CPT, HPT) with the method of limits
Description: The testing will be carried out using the classical method of limits, i.e. a continuous heating/cooling stimulus will be applied to the skin at a rate of 1°C/s, until the subject signals that he/she felt the targeted sensation by pressing a button (Rolke, Baron, et al., 2006). The temperature reached by the time the subject pressed the button will be considered the threshold. Baseline temperature will be set at 32°C. The stimuli will not go lower than 0°C and higher than 50°C.
Study NCT03004638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received 3 doses of placebo matching with MEDI6012 intravenously (IV) on Days 1, 8, and 15.
Study NCT03004638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI6012 120 mg
Description: Participants received 3 doses of 120 mg MEDI6012 IV on Days 1, 8, and 15.
Study NCT03537924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
Study NCT03537924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study NCT03793881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Strategy
Description: Counseling based on dietary goals and mindfulness techniques.
Study NCT03793881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Prescription
Description: Dietary prescription according to guidelines.
Study NCT04174092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: completing self-questionnaires
Description: completing self-questionnaires on quality of life, anxiety, insomnia, activity of rheumatic disease and catastrophism
Study NCT00793416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shunt flow detection
Description: Shunt flow detection based upon ShuntCheck results compared to radionuclide test results
Study NCT02824913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-321 Ophthalmic Solution
Study NCT02824913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: P-321 Ophthalmic Solution placebo
Study NCT03900260 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Softec HP1 Intraocular Lens
Description: The Softec HP1 IOL is a single-piece, biconvex, ultraviolet absorbing intraocular lens designed for insertion into the posterior chamber of the human eye for visual correction of Aphakia in adults over the age of 21, and as a replacement of a damaged (cataract) natural lens.
Study NCT02600130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Longeveron Mesenchymal Stem Cells
Description: via peripheral intravenous infusion